نتائج البحث

Post-COVID-19 Condition After SARS-CoV-2 Infections During the Omicron Surge vs the Delta, Alpha, and Wild Type Periods in Stockholm, Sweden

• Authors : Hedberg, P; Naucler, P

Subjects: Medicin och hälsovetenskap

• Source: The Journal of infectious diseases. 229(1):133-136

تفاصيل العنوان

Potential Biomarkers for IDH-Mutant and IDH-Wild-Type Glioblastomas: A Single-Center Retrospective Study.

• Authors : Sarac, Mustafa Emre¹ (AUTHOR) ; Boga, Zeki^1,2 (AUTHOR); Kara, Ümit^1,2 (AUTHOR)

• Source: Journal of Clinical Medicine. Apr2025, Vol. 14 Issue 7, p2518. 16p.

تفاصيل العنوان

Inhibition of Mdm2-p53 interaction as a therapeutic strategy for the treatment of p53 wild-type rhabdomyosarcoma

• Authors : Pons Barcons, Guillem;

Subjects: PARP; MDM2; Rabdomiosarcoma

• Source: TDX (Tesis Doctorals en Xarxa)

تفاصيل العنوان

Fc fragment of IgG binding protein suppresses tumor growth by stabilizing wild type P53 in colorectal cancer cells

• Authors : Jiefu Wang; Ziqing Gong; Jia Liu

Subjects: Fc fragment of IgG binding protein; Colorectal cancer; Wild type P53

• Source: BMC Cancer, Vol 25, Iss 1, Pp 1-9 (2025)

تفاصيل العنوان

Complement Components in Peripheral Blood from Adult Patients with IDH Wild-Type Glioblastoma

• Authors : Förnvik Jonsson, Karolina; Liljedahl, Emma; Osther, Kurt ...

Subjects: Medical and Health Sciences; Basic Medicine; Immunology in the Medical Area (including Cell and Immunotherapy)

• Source: World Neurosurgery. 177:e742-e747

تفاصيل العنوان

Targeted Therapy With CDK4/6 Inhibitors in Chemo-Refractory, Rb Wild-Type Extensive SCLC

• Source: Targeted Therapy With CDK4/6 Inhibitors in Chemo- Refractory/Relapsed, Rb Wild-type Extensive Small Cell Lung Cancer (SCLC), Large Cell

تفاصيل العنوان

Binimetinib for People With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

• Source: Phase 2 Trial for Binimetinib for Patients With Relapsed/Refractory BRAF Wild Type Hairy Cell Leukemia and Variant

تفاصيل العنوان

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy (OrigAMI-3)

• Source: A Randomized, Open-label Phase 3 Study of Amivantamab + FOLFIRI Versus Cetuximab/Bevacizumab + FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-

تفاصيل العنوان

A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer (OrigAMI-2)

• Source: A Randomized, Open-label Phase 3 Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF

تفاصيل العنوان

A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

• Authors : National Institutes of Health (NIH); Biohaven Pharmaceuticals, Inc.; Eudocia Quant Lee, MD, Sponsor Investigator

• Source: A Surgical Window of Opportunity Clinical Trial of Troriluzole in Recurrent IDH Wild-Type Glioblastoma

تفاصيل العنوان